Clinical Trial Update: A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial evaluating KT-621 taken orally in adults with moderate-to-severe eosinophilic asthma; recruitment is currently ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• KT-621

Snippet

Sponsor: Kymera Therapeutics, Inc. | Conditions: Eosinophilic Asthma | Phase 2 | Status: RECRUITING